

# Improving Machine Learning Prediction of ADHD Using Gene Set Polygenic Risk Scores and Risk Scores from Genetically Correlated Phenotypes

Eric Barnett<sup>1,2</sup>, Yanli Zhang-James<sup>3</sup>, Stephen V Faraone<sup>1,3\*</sup>

## Affiliations

<sup>1</sup>Department of Neuroscience and Physiology, SUNY Upstate Medical University, Syracuse, New York, USA

<sup>2</sup>College of Medicine, MD Program, SUNY Upstate Medical University, Syracuse, New York, USA

<sup>3</sup>Department of Psychiatry and Behavioral Sciences, SUNY Upstate Medical University, Syracuse, New York, USA

## \*Corresponding Author:

Stephen V. Faraone, PhD

SUNY Upstate Medical University

750 East Adams St.

Syracuse, NY 13210

svfaraone@upstate.edu

315-464-3113, 315-464-3279 (fax)

## Abstract

**Background:** Polygenic risk scores (PRSs), which sum the effects of SNPs throughout the genome to measure risk afforded by common genetic variants, have improved our ability to estimate disorder risk for Attention-Deficit/Hyperactivity Disorder (ADHD) but the accuracy of risk prediction is rarely investigated.

**Methods:** With the goal of improving risk prediction, we performed gene set analysis of GWAS data to select gene sets associated with ADHD within a training subset. For each selected gene set, we generated gene set polygenic risk scores (gsPRSs), which sum the effects of SNPs for each selected gene set. We created gsPRS for ADHD and for phenotypes having a high genetic correlation with ADHD. These gsPRS were added to the standard PRS as input to machine learning models predicting ADHD. We used feature importance scores to select gsPRS for a final model and to generate a ranking of the most consistently predictive gsPRS.

**Results:** For a test subset that had not been used for training or validation, a random forest (RF) model using PRSs from ADHD and genetically correlated phenotypes and an optimized group of 20 gsPRS had an area under the receiving operating characteristic curve (AUC) of 0.72 (95% CI: 0.70 – 0.74). This AUC was a statistically significant improvement over logistic regression models and RF models using only PRS from ADHD and genetically correlated phenotypes.

**Conclusions:** Summing risk at the gene set level and incorporating genetic risk from disorders with high genetic correlations with ADHD improved the accuracy of predicting ADHD. Learning curves suggest that additional improvements would be expected with larger study sizes. Our study suggests that better accounting of genetic risk and the genetic context of allelic differences results in more predictive models.

## Introduction

The field of psychiatric genomics has made great strides discovering genetic loci that are significantly associated with psychiatric disorders [1-3]. These discoveries have generated new hypotheses about the genomic architecture complex pathogenesis of many of these disorders. The combination of risk conferring alleles has improved the prediction of psychopathology [4].

A multi-site ADHD GWAS found that 12 genome-wide-significant loci captured a small amount of the heritability of ADHD while risk profiles using all loci captured a significantly larger amount of heritability, which proved the usefulness of loci that are, individually, are not significantly different between cases and controls [1]. Even in this study of over 20,000 people with ADHD, the complex genetic architecture of the disorder makes predicting generalizable risk and establishing significance at each common variant difficult.

Previous work has shown that ADHD has significant genetic overlaps with other psychiatric and non-psychiatric disorders [5-10]. This supports the theory that ADHD risk comprises traits that are also present in the phenotypes with which it is genetically correlated. The risk estimation of SNPs in genetically correlated disorders could be more predictive in ADHD relative to the risk estimation of SNPs in ADHD GWASs due to larger sample sizes being better for estimating risk. In addition, when dealing with disorders with high heterogeneity like ADHD it is possible that other less heterogeneous phenotypes better estimate risk for genetic loci for some clusters of patients. Therefore, using the genetic overlap with other disorders could be useful in improving the predictive modeling of ADHD.

A review of twin-studies of ADHD found that the mean heritability of ADHD across 37 studies was 74% [11]. The high heritability of ADHD suggests that predicting ADHD using genetic and environmental data is achievable. However, reports on predictive models of ADHD using genetic data is limited. Significant improvements in prediction and our understanding of the

disorder must be made before genetic information can be used in the clinic as part of future objective diagnoses and personalized medicine plans that aim to improve outcomes in ADHD.

One potential area of improvement is balancing the flexibility of models to detect robust risk patterns with complexity and generalizability. Combining the risk at SNPs across the genome into a single polygenic risk score (PRS) has proven to be a successful way to create a more useful and generalizable feature than any individual SNP[12]. However, summing all SNPs into a single value per individual limits any modelling method's capacity to learn more complicated patterns and interactions. On the other end of the complexity spectrum, using individual SNPs as input into machine learning models of complex and heterogenous disorders like ADHD leads to concerns of overfitting and lack of generalizability [13]. Combining risk at the gene set level could be an effective middle ground between these two extremes. While research using features combining risk at the gene set level to predict a disorder is limited, gene set association analyses have shown that this middle ground can be useful.

While machine learning classification models of ADHD using genomic data have not been reported, many researchers have used such models to predict diagnoses for other heritable complex disorders[14-18]. Collectively, these studies have shown the potential of machine learning to predict many disorders but concerns of how well these models would perform on unseen external data sets remain. In addition, many machine learning methods generate "black-box" models that are uninterpretable. Since most models lack the performance necessary for clinical application, interpretable models may provide additional useful results apart from the model that would otherwise only be an intermediate to eventual models that will be useful clinically. Interpretable genomic models could yield biological insights by finding new loci of interest or new groups of loci that together improve models. These models also could incorporate further model validation by relating the output to our understanding of the biology behind the disorder.

Here, we balance these issues by summing risk across gene sets to create gene set polygenic risk scores (gsPRSs) that may be used alongside PRS to improve predictive accuracy by providing the model with information about gene sets associated with ADHD. We hypothesized that including gsPRSs as input into machine learning models would improve prediction performance compared to models that use only traditional PRS. We also supplemented the model with summary statistics from phenotypes with high genetic correlations with ADHD as additional features to test if these information are useful to improve ADHD prediction.

## **Methods**

### Data Preprocessing and Splitting

Quality control and imputation were done using the RICOPILI pipeline[19]. After quality control, 2455 ADHD cases and 8432 controls across 9 cohorts aggregated by the PGC were available for analysis [1]. We excluded SNPs with a minor allele frequency  $< 0.01$ , missing genotype rate  $> 0.05$ , and deviating from Hardy-Weinberg equilibrium in controls at  $p < 1 \times 10^{-5}$ . The participants were randomly split into a training subset containing 1673 cases and 5818 controls, a validation subset containing 406 cases and 1329 controls, and a test subset containing 376 cases and 1285 controls. The training subset was used to teach the model to differentiate different cases and controls by optimizing the parameters within the model. The validation subset was used to estimate the model performance outside examples used to train the model and to optimize model hyper-parameters. The test subset was used for reporting the results of our final models on an unseen sample.

### Gene Set Association Analysis

Using the SNP association p-values generated in the SNP association analysis, we used MAGMA to compare allele frequencies between cases and controls at the gene and gene sets level [20]. Both analyses used an extended gene window starting 35 kilobases upstream and

ending 10 kilobases downstream of each gene to account for cis regulatory elements. The complete MsigDB gene ontology gene sets collection was used as input into the analysis. The gene sets most associated with this study sample have been previously reported [1].

### Polygenic Risk Scoring

From the associations collected from gene set analysis, we selected the most associated gene sets based on their p-values. To avoid including the same risk signal multiple times within a score, we adjusted SNPs tagging each gene set for linkage disequilibrium using PRS-CS, a tool that infers posterior effect sizes of each SNP after removing overlaps due to linkage disequilibrium. From these adjusted SNPs, we used polygenic weighted scoring to generate a risk profile for each gene set in each subject using Plink. We calculated genome-wide polygenic risk profiles using the same combination of PRS-CS and Plink scoring. For comparison, we also generated PRS using the clumping and thresholding method.

### Correlated Trait/Disorder Polygenic Risk Scoring

We calculated additional risk profiles using SNP effects estimated from GWASs of disorders and traits with the highest genetic correlation with ADHD and heritability over 0.1 found using GWAS Atlas[21]. After excluding similar phenotypes based on study size, the included phenotypes were age at first sexual intercourse[21], opioid use[22], college completion[23], childhood IQ[24], childhood extreme obesity[25], autism spectrum disorder[26], time spent watching television[21], psychiatric cross-disorder risk[27], intracranial volume[28], age at menopause[21], and myopia[21]. We calculated the gsPRS for genetically correlated disorders on the gene sets most associated with ADHD diagnosis by using the SNP effects from the summary statistics for each trait in additional MAGMA gene set analyses. We included PRS and 100 gsPRS for each trait/disorder in machine learning feature selection.

## Machine Learning Preprocessing and Feature Selection

We adjusted each polygenic risk score for ancestry by extracting the top 5 principal components from a principal components analysis (PCA) of the training subset and using those 5 principal components in a generalized linear model predicting each polygenic risk score. We replaced the unadjusted polygenic risk score with the residual of each prediction using the 5 principal components. We normalized each score between 0 and 1 using min-max normalization and balanced cases and controls in each subset by random case up-sampling with replacement.

For gsPRS only models, we started by selecting gsPRS from the 40 gene sets most associated with ADHD within the training subset. We optimized the hyperparameters of a random forest based on this initial set of features. Then, we performed a random iterative feature selection process in which we kept and recorded the most important features, based on the permutation feature importance calculated from the mean difference in Gini impurity, and randomly replaced the less important features with a different gsPRS feature until the model found a set of gsPRS that outperformed the previous best set. We reoptimized the random forest hyperparameters at regular intervals and repeated the random replacement process such that each feature would likely be included in multiple iterations of the newly optimized model. At the end of this process, we selected the best group of 20 gsPRS for model performance evaluation.

In the models that included gsPRS and PRS-CS, we used the same random iterative feature selection approach used in the gsPRS only model, but also included the genome-wide PRS-CS scores calculated from the training subset and summary statistics from GWAS of related disorders in every model.

## Machine Learning Model Optimization

Within Scikit-learn, we used grid search optimization to select the best hyperparameters for all models using the AUC in the validation subset [29]. We optimized multiple types of models to

better compare the performance of different methods within the validation subset and select the best model for this application. Exploring multiple models is essential given that for any given problem, one algorithm may be ideal but it is not possible, in advance, to know what algorithm will be best [30]. For random forest (RF) models, we optimized number of trees in the forest, maximum depth of the tree, and the number of features to consider when looking for the best split. For support vector machine (SVM) models, we optimized C, which balances misclassification against simplicity, and gamma, which determines the effect of a single training example on the model. For k-nearest neighbor (kNN) models, we optimized number of neighbors, leaf size, weight function, and the power parameter for the Minkowski metric. For the PRS and PRS-CS models, we fit logistic regression models to compare performance with our more complex models using the glm package in R. We fit the lasso model using all PRS-CS and all gsPRS as input using the glmnet package in R.

### Model Performance Evaluation and Feature Importance Tracking

To measure the performance of the models selected with grid search optimization we used area under the receiver operating characteristic curve (AUC) in the test subset. Data leakage is a common issue in machine learning research normally caused by inadvertently learning information about the test data that improves performance in those specific data. One way data leakage can occur is through testing many models on the test data, which increases the chance of selecting a model that is randomly configured in a way that is more optimal for the test data but not generalizable. With the goal of minimizing data leakage that might bias our results towards the test data, we tested model performance in the test subset only on the model with the highest AUC in the validation subset for each analysis. We estimated the known genetic variance explained by each of the models using a formula developed for the genetic interpretation of AUCs using 0.75 as the heritability estimate and 0.05 as the prevalence



estimate[31]. We compared AUCs from different models using DeLong's test for two correlated ROC curves. We also tested the probability of achieving the AUC in the best gsPRS grouping by comparing the AUC in the test subset with the distribution of AUCs from 10,000 models with random gsPRS groups of the same size. All models included the PRS for all correlated phenotype summary statistics. We used learning curves to model whether additional training examples would improve model performance and to compare models.

To calculate a more generalizable importance score for each gsPRS outside of the best group of gsPRS, we estimated feature importance for each gsPRS and PRS-CS feature in RF models with a random group of gsPRS calculated from gene sets associated with ADHD and tracked the permutation feature importance that measures the decrease in model performance when a single feature value is randomly shuffled. We calculated the mean feature importance of each gsPRS across 10,000 models that used 40 random gsPRSs each. We did not use feature importance scores calculated from the test subset for feature selection or any optimization.

### Testing Biological Relevance of gsPRS Feature Importance

To further validate our methods by testing for correlations with the known neurobiology of ADHD, we computed correlations between tissue-specific gene expression and feature importance [32, 33]. For ADHD, we would expect that most gene sets truly associated with the disorder would be more relevant to the brain and less relevant to other tissues. Therefore, if the importance of the gsPRS generated in our analysis are correlated with brain expression relative to all other tissues, we can be more confident that gsPRSs are collectively picking up a real generalizable risk feature instead of modelling random noise. We used a dataset containing gene expression data for 54 tissue types from the genotype-tissue expression (GTEx) project. We combined this gene expression data into gene set expression data for the same gene sets used in the gsPRSs. We estimated relative gene set expression in the brain using the Preferential Expression Measure formula which estimates how different the expression of a

gene is relative to the expected expression level. We fit a linear model predicting gene set expression in brain tissues relative to non-brain tissues using the MAGMA gene set association p-value to establish a baseline. We fit a linear model using the base model with gsPRS feature importance as a second predictor to test for association of gene set expression with gsPRS importance score after controlling for MAGMA gene set associations. We fit linear models with the same dependent and independent variables using only gene sets calculated from the ADHD training subset or from the group of correlated phenotypes to test whether each group was independently associated with gene set expression. To test whether the association between mean importance score and relative gene set brain expression in the brain was dependent on whether the gsPRS was calculated from the ADHD training subset, we estimated predictive margins using STATA16's margins command, which computes the average probability for each observation at a fixed level of a selected variable. In our analyses, these predictive margins estimate the average relative gene set expression in the brain for each gsPRS while fixing the ADHD vs non-ADHD variable to each value. A meta-analysis on subcortical brain volume differences in ADHD found that the volumes of the accumbens, amygdala, caudate, hippocampus, and putamen were smaller in participants with ADHD [34]. We fit linear models predicting gene expression in these brain regions implicated in ADHD relative to all other brain regions with gene set expression as the dependent variable and MAGMA gene set association p-value and gsPRS feature importance.

## **Results**

### Model performance

To establish baseline performance, we measured the prediction performance in the test subset of a logistic regression with the PRS calculated from the training subset. This PRS only logistic regression had an AUC of 0.62 (95% CI: 0.60 – 0.64) in the test subset and explained 5.0% of the known genetic variance. Replacing PRS with PRS-CS in another logistic regression model

led to an AUC of 0.66 (Figure 1; 95% CI: 0.64 – 0.68) and explained 9.0% of the known genetic variance. We then measured the performance of logistic regression and random forest models containing the PRS-CS from the training subset and PRS-CS calculated from summary statistics from phenotypes with a heritability above 0.1 with the highest genetic correlation to ADHD (Table 1). The logistic regression model had an AUC of 0.66 (95% CI: 0.64 – 0.68) while a random forest model using the same input had an AUC of 0.69 (Figure 1; 95% CI: 0.67 – 0.71) in the test subset and explained 12.8% of the known genetic variance.

After using our feature selection method to select the best group of 20 gsPRS, we trained a random forest model using the selected group and all PRS-CS. In the test subset, this model had an AUC of 0.72 (Figure 1; 95% CI: 0.70 – 0.74) and explained 17.4% of the known genetic variance. This was a significant improvement in comparison to the RF that included only the PRS-CS from each trait ( $p = 0.0057$ , DeLong's test for two correlated ROC curves). The RF model with all PRS-CS and the best group of 20 gsPRS also had a significantly higher AUC ( $p = 1.2 \times 10^{-6}$ , DeLong's test for two correlated ROC curves). compared to a lasso model fit with all PRS-CS and gsPRS as input, which had an AUC of 0.65 (95% CI: 0.63 – 0.67). The AUC of the best group model was greater than 99.6% of the 10,000 random group models. The mean AUC of the random group models was 0.69. All the gene sets used in the random groups were associated with ADHD in the training subset with a p-value of less than 0.05 without correction for multiple testing. SVM and kNN models were less predictive than RF models in the validation subset, so we did not test them on the test subset.

We trained and optimized another random forest model using only gsPRS. The model had an AUC of 0.61 (95% CI: 0.59 – 0.63) in the test subset. The AUC of the best group model was greater than 99.1% of the 10,000 random group models.

## Random Forest Learning Curve and Feature Importance Analyses

For the best random forest model, we generated a learning curve (Figure 2) that plots the AUC against the number of training examples[35]. We also optimized a random forest model using only PRS-CS and generated a learning curve (Figure 3) for comparison.

Using the optimized random forest model, we generated feature importance scores in the test subset for all the features used in the model. The most important features and their importance scores are listed in Table 2. In addition, we calculated the average feature importance in the test subset across 10,000 random group of 40 gsPRS only models (princTable 1).

## Testing Biological Relevance of gsPRS Feature Importance

The base linear model we fit with relative gene set expression as the dependent variable and MAGMA gene set association p-value as the independent variable showed a significant negative correlation between the two variables ( $p = 1 \times 10^{-5}$ ). The model adding mean gsPRS importance score as an independent variable showed a significant positive correlation between mean gsPRS importance score and relative gene set expression after controlling for MAGMA gene set association p-value ( $p = 2 \times 10^{-4}$ ). We found no significant differences in gene expression between brain regions implicated in ADHD and other brain regions.

The base + mean gsPRS feature importance model we fit using only gsPRS calculated from the ADHD training subset showed a significant positive correlation between mean gsPRS importance score and relative gene set expression in the brain ( $p = 0.008$ ). The same model fit using only gsPRS calculated from the correlated phenotypes also showed a significant positive correlation between mean gsPRS importance score and relative gene set expression in the brain ( $p = 0.003$ ). An additional linear model we fit adding an independent variable specifying whether the gsPRS was calculated in the ADHD training subset or a correlated phenotype and that variable's interaction with importance score showed that the correlation of gene set

expression in the brain with mean gsPRS importance was negatively dependent on whether the gsPRS was calculated in the ADHD training subset ( $p = 5 \times 10^{-4}$ ). As illustrated in Figure 4, our predictive margins analysis of this interaction estimated a significant positive association with a slope of 4.7 ( $p < 0.001$ ) when the variable indicating development in the ADHD training subset was fixed to 0, meaning the gsPRS was developed using one of the correlated phenotypes, and a significant positive association with a slope of 0.60 ( $p = 0.015$ ) when the same variable was fixed to 1, meaning the gsPRS was developed using the ADHD training subset.

## Discussion

This study is the first to produce gene set specific risk profiles predicting the presence/absence of a psychiatric disorder with machine learning. The addition of optimized groups of gsPRS to genome wide PRS-CS significantly improves prediction performance compared to both models without gsPRS and models with random groups of gsPRS. We further validated these results by testing for biological correlation of the random forest importance scores, which showed that importance scores were significantly positively associated with increased relative gene set expression in the brain.

Compared to simpler models that rely on a single PRS value per individual and more complex models that rely on “black-box” dimension reduction methods, gsPRS models have the potential of offering more interpretability and have the possibility to shed light on mechanisms involved in risk prediction and test specific gene set hypotheses. To improve interpretation of our models, we generated two sets of feature importance measurements that capture similar, but distinct information regarding the predictiveness of gsPRS. The feature importance measurements from the best group of gsPRS (Table 2) show how useful each gsPRS and PRS-CS were in that specific model. Unsurprisingly, the ranking is led by the PRS-CS from a cross-disorder GWAS that studied the shared risk across multiple psychiatric disorders including ADHD and the PRS-CS calculated from the training subset. Those PRS-CS are followed by a group of gsPRS that

collectively led to significant improvements in prediction. It is likely that this group contains less overlapping risk information relative to other groupings since such overlaps would increase model complexity without adding value for prediction. However, overlapping gsPRS could still be important individually or in different groupings. Therefore, we calculated average gsPRS feature importance in 10,000 models that each used 40 gsPRS as input. This average represents how often and how strongly each gsPRS was able to improve prediction.

With this list of gsPRSs and their feature importance, we sought to further validate our methods by testing for correlations with what is known about the neurobiology of ADHD [32, 33]. Our baseline regression analysis found a significant negative correlation between relative gene set expression in the brain and MAGMA gene set association p-value. This met our expectation since MAGMA is a widely used tool and we would expect that gene sets more associated with ADHD and correlated phenotypes would be correlated with increased relative expression of that gene set in the brain, which is consistent with the report of Demontis et al [1]. Our analysis adding mean gsPRS importance score to the baseline regression analysis found that, even after correcting for MAGMA gene set association, mean gsPRS importance score was significantly positively correlated with relative gene set expression in the brain. This suggests that the mean gsPRS importance scores can be used to select biologically relevant gene sets beyond their association with ADHD as calculated using MAGMA. This finding suggests that combining MAGMA and mean gsPRS importance scores could provide a better way to prioritize gene sets for future study compared with using MAGMA alone.

We were also interested to test whether the correlations between relative gene set expression in the brain and mean gsPRS importance scores were dependent on whether the gsPRS was calculated using the ADHD training subset or from summary statistics of the correlated phenotypes. In both groups (ADHD and correlated phenotypes), the correlation between gene set expression and importance scores remained significant but the correlation of relative gene

set expression in the brain and gsPRS importance score was stronger when the gsPRS was developed using summary statistics from correlated phenotypes (see Figure 4). This finding may seem counterintuitive, considering that most of the gsPRS from other phenotypes had low gsPRS importance scores relative to the gsPRS calculated using the ADHD training subset. However, when a gsPRS from a correlated phenotype is predictive in ADHD that gene set has shown an association and importance in its initial study, the ADHD training subset in our study, and the ADHD test subset in our study. We find it unsurprising that gsPRSs calculated from such generalizable gene sets would be more likely to represent true risk signals and therefore be more likely to have increased relative gene set expression values in the brain.

The learning curves suggest that the performance improvements from gsPRS should increase with increasing sample size. More complex models generally require more data to train, as demonstrated by the early stages of the learning curve that show perfect training subset performance and no predictability in the validation subset as the model is complex enough and sample size is low enough to memorize the training data instead of learning patterns among those data. In both learning curves, it is evident that the model is better at predicting the training data compared to the validation data even after selecting hyperparameters that specifically maximize prediction in the validation subset. This further illustrates the importance of testing performance on data the model does not learn from during training to get an accurate representation of model performance and generalization. As training size increases, the model can no longer rely on memorization and starts to learn patterns that generalize to the validation subset. The continued validation subset prediction improvements at the highest training sizes suggest that the model could still benefit from more training data. In comparison, the learning curve of a random forest model using only PRS-CS shows a quick plateau to optimal performance and additional training size does not further improve performance.

Our study has several limitations that could limit performance. To best estimate model performance and reduce overfitting, we split our data into several subsets, thereby limiting the number of study participants available to train the models. We also adjusted for the effects of the top 5 principal components in a PCA of the training subset to control for ancestry. This adjustment could inadvertently remove non-confounding information that might have improved performance and likely does not remove all ancestry information. A better method of selectively removing known confounders like ancestry would likely further improve both the performance and generalizability of these models. The gene sets we used to sum sets of SNPs into gsPRS, although capture the biological functions and pathways, may not be ideally suited for prediction tasks. A more data-driven approach to develop sets of SNPs that best collectively predict diagnosis may be necessary to maximize prediction performance.

More advanced machine learning methods and architectures may also lead to more predictive models. Including data beyond genotype information like clinical data and data that captures at least a portion of the environmental component of ADHD pathology could help machine learning models better estimate ADHD risk and better separate ADHD cases and controls. With the right set of interpretation tools, models that can accurately discriminate ADHD cases and controls would be useful in improving our understanding of the disorder and allow for testing specific hypotheses.

### **Acknowledgements**

This project has received funding from the European Union's Horizon 2020 research and innovation programme grant agreement No 667302. This project has received funding from the European Union's Horizon 2020 research and innovation programme grant agreement No 965381.



The data used for the gene expression analyses described in this manuscript were obtained from the Genotype-Tissue Expression (GTEx) Portal. The GTEx Project was supported by the Common Fund of the Office of the Director of the National Institutes of Health, and by NCI, NHGRI, NHLBI, NIDA, NIMH, and NINDS.

### **Financial Disclosures**

In the past year, Dr. Faraone received income, potential income, travel expenses continuing education support and/or research support from Aardvark, Akili, Genomind, Ironshore, KemPharm/Corium, Noven, Ondosis, Otsuka, Rhodes, Supernus, Takeda, Tris and Vallon. With his institution, he has US patent US20130217707 A1 for the use of sodium-hydrogen exchange inhibitors in the treatment of ADHD. In previous years, he received support from: Alcobra, Arbor, Aveksham, CogCubed, Eli Lilly, Enzymotec, Impact, Janssen, Lundbeck/Takeda, McNeil, NeuroLifeSciences, Neurovance, Novartis, Pfizer, Shire, and Sunovion. He also receives royalties from books published by Guilford Press: *Straight Talk about Your Child's Mental Health*; Oxford University Press: *Schizophrenia: The Facts*; and Elsevier: *ADHD: Non-Pharmacologic Interventions*. He is also Program Director of [www.adhdinadults.com](http://www.adhdinadults.com).

Dr. Faraone is supported by NIMH grants U01MH109536-01, U01AR076092-01A1, R0MH116037 and 5R01AG06495502; Oregon Health and Science University, Otsuka Pharmaceuticals and Supernus Pharmaceutical Company.


Dr. Yanli Zhang-James is supported by the European Union's Seventh Framework Programme for research, technological development and demonstration under grant agreement no 602805 and the European Union's Horizon 2020 research and innovation programme under grant agreements No 667302.

Eric Barnett has no financial disclosures.


## Data Availability

Supplementary Data contains all information on data availability for summary statistics with links. Individual-level genotype data are available upon request to the Psychiatric Genomics Consortium (PGC).


**Figure 1. Model ROC Comparison.** The logistic regression model using traditional PRS methods had an AUC of 0.62 (95% CI: 0.60 – 0.64). The logistic regression model using PRS-CS methods had an AUC of 0.66 (95% CI: 0.64 – 0.68). The random forest model using PRS-CS and an optimized group of 20 gsPRS had an AUC of 0.72 (95% CI: 0.70 – 0.74).




**Figure 2. Learning Curves for gsPRS + PRS-CS Random Forest Model.** The learning curve analysis of the random forest model containing all PRS-CS and the best group of 20 gsPRS. Each point represents the accuracy of the model when trained with a set number of training examples.



**Figure 3. Learning Curves for PRS-CS only Random Forest Model.** The learning curve analysis of the random forest model containing all PRS-CS. Each point represents the accuracy of the model when trained with a set number of training examples.



**Figure 4. Predictive Margins Analysis of Interaction between Importance Score and Relative Gene Set Expression.** When the variable indicating gsPRS development in the ADHD training subset was fixed to 0 (developed in a correlated disorder) there was a significant positive association with a slope of 4.7 ( $p < 0.001$ ). When the variable was fixed to 1 (developed in the ADHD training subset) there was a significant positive association with a slope of 0.60 ( $p = 0.015$ ).



**Table 1. Summary statistics from genetically correlated phenotypes that were used to generate additional genetic risk features.**

Trait	rg	N	SNP.h2
Age at first sexual intercourse	-0.584	339614	0.1132
Opioid use	0.565	78808	0.146
College completion	-0.524	95427	0.105
Childhood IQ	-0.461	12441	0.2744
Extreme obesity (childhood)	0.436	7916	0.5078
Autism spectrum disorder	0.384	46350	0.1944
Time spent watching television (TV)	0.372	365236	0.1023
PGC cross disorder	0.262	61220	0.1715
Intracranial Volume	-0.248	26577	0.2467
Myopia	-0.217	78647	0.1532

**Table 2. Top feature importance scores for the best group of gsPRS and PRS random forest model.**

Feature	Phenotype	Importance
Genome Wide Polygenic Risk Score	pgc cross disorder	0.0324
Genome Wide Polygenic Risk Score	training subset	0.0250
GO_CELLULAR_RESPONSE_TO_ENDOGENOUS_STIMULUS	training subset	0.0055
GO_POSITIVE_REGULATION_OF_PROTEIN_MODIFICATION_PROCESS	training subset	0.0044
GO_RESPONSE_TO_TOXIC_SUBSTANCE	training subset	0.0032
GO_REGULATION_OF_PRESYNAPSE_ORGANIZATION	training subset	0.0027
GO_REGULATION_OF_PLASMA_LIPOPROTEIN_PARTICLE_LEVELS	training subset	0.0026
GO_POSITIVE_REGULATION_OF_TRANSFERASE_ACTIVITY	training subset	0.0026
GO_PRESYNAPSE_ORGANIZATION	training subset	0.0025
GO_SYNAPTIC_SIGNALING	pgc cross disorder	0.0024
Genome Wide Polygenic Risk Score	age first had sexual intercourse	0.0022
GO_REGULATION_OF_VASCULAR_PERMEABILITY	training subset	0.0019
GO_PRIMARY_ALCOHOL_BIOSYNTHETIC_PROCESS	training subset	0.0018
GO_HEAD_DEVELOPMENT	pgc cross disorder	0.0017
GO_LIPASE_ACTIVITY	training subset	0.0017
GO_REGULATION_OF_NEURON_DIFFERENTIATION	pgc cross disorder	0.0014
GO_MICROTUBULE_PLUS_END_BINDING	training subset	0.0013
GO_NEURON_DIFFERENTIATION	pgc cross disorder	0.0012
GO_CEREBELLAR_GRANULAR_LAYER_FORMATION	training subset	0.0011
GO_SOMATODENDRITIC_COMPARTMENT	pgc cross disorder	0.0009
GO_POSITIVE_REGULATION_OF_EXCITATORY_POSTSYNAPTIC_POTENTIAL	training subset	0.0008
GO_REGULATION_OF_MEMBRANE_POTENTIAL	pgc cross disorder	0.0008

## References

1. Demontis, D., et al., *Discovery of the first genome-wide significant risk loci for attention deficit/hyperactivity disorder*. Nat Genet, 2019. **51**(1): p. 63-75.
2. Stahl, E.A., et al., *Genome-wide association study identifies 30 loci associated with bipolar disorder*. Nat Genet, 2019. **51**(5): p. 793-803.
3. Psychiatric Genomics Consortium, *Biological insights from 108 schizophrenia-associated genetic loci*. Nature, 2014. **511**(7510): p. 421-7.
4. Smoller, J.W., et al., *Psychiatric genetics and the structure of psychopathology*. Mol Psychiatry, 2019. **24**(3): p. 409-420.
5. Rommelse, N.N., et al., *Shared heritability of attention-deficit/hyperactivity disorder and autism spectrum disorder*. Eur Child Adolesc Psychiatry, 2010. **19**(3): p. 281-95.
6. Cole, J., et al., *Genetic overlap between measures of hyperactivity/inattention and mood in children and adolescents*. J Am Acad Child Adolesc Psychiatry, 2009. **48**(11): p. 1094-101.
7. Brikell, I., et al., *Familial Liability to Epilepsy and Attention-Deficit/Hyperactivity Disorder: A Nationwide Cohort Study*. Biol Psychiatry, 2018. **83**(2): p. 173-180.
8. Chen, Q., et al., *Shared familial risk factors between attention-deficit/hyperactivity disorder and overweight/obesity - a population-based familial coaggregation study in Sweden*. J Child Psychol Psychiatry, 2017. **58**(6): p. 711-718.
9. Faraone, S.V., et al., *The Familial Co-Aggregation of Attention-Deficit/Hyperactivity Disorder and Intellectual Disability: A Register-Based Family Study*. J Am Acad Child Adolesc Psychiatry, 2017. **56**(2): p. 167-174 e1.
10. Skoglund, C., et al., *Attention-deficit/hyperactivity disorder and risk for substance use disorders in relatives*. Biol Psychiatry, 2015. **77**(10): p. 880-6.

11. Faraone, S.V. and H. Larsson, *Genetics of attention deficit hyperactivity disorder*. Mol Psychiatry, 2018, 24(4):562-575
12. Wray, N.R., et al., *From Basic Science to Clinical Application of Polygenic Risk Scores: A Primer*. JAMA Psychiatry, 2020, 78(1):101-109
13. Ying, X., *An Overview of Overfitting and its Solutions*, in *IOP Conf. Series: Journal of Physics: Conf. Series 1168 (2019) 022022*. 2019, IOP Publishing.
14. Wei, Z., et al., *Large sample size, wide variant spectrum, and advanced machine-learning technique boost risk prediction for inflammatory bowel disease*. Am J Hum Genet, 2013. **92**(6): p. 1008-12.
15. Mittag, F., M. Römer, and A. Zell, *Influence of Feature Encoding and Choice of Classifier on Disease Risk Prediction in Genome-Wide Association Studies*. PLoS One, 2015. **10**(8): p. e0135832.
16. Evans, D.M., P.M. Visscher, and N.R. Wray, *Harnessing the information contained within genome-wide association studies to improve individual prediction of complex disease risk*. Hum Mol Genet, 2009. **18**(18): p. 3525-31.
17. Wang, Y., et al., *Random Bits Forest: a Strong Classifier/Regressor for Big Data*. Sci Rep, 2016. **6**: p. 30086.
18. Almlöf, J.C., et al., *Novel risk genes for systemic lupus erythematosus predicted by random forest classification*. Sci Rep, 2017. **7**(1): p. 6236.
19. Lam, M., et al., *RICOPILI: Rapid Imputation for COnsortias PlpeLIne*. Bioinformatics, 2020. **36**(3): p. 930-933.
20. de Leeuw, C.A., et al., *MAGMA: generalized gene-set analysis of GWAS data*. PLoS Comput Biol, 2015. **11**(4): p. e1004219.



21. Watanabe, K., et al., *A global overview of pleiotropy and genetic architecture in complex traits*. Nat Genet, 2019. **51**(9): p. 1339-1348.
22. Wu, Y., et al., *Genome-wide association study of medication-use and associated disease in the UK Biobank*. Nat Commun, 2019. **10**(1): p. 1891.
23. Rietveld, C.A., et al., *GWAS of 126,559 individuals identifies genetic variants associated with educational attainment*. Science, 2013. **340**(6139): p. 1467-71.
24. Benyamin, B., et al., *Childhood intelligence is heritable, highly polygenic and associated with FBNP1L*. Mol Psychiatry, 2014. **19**(2): p. 253-8.
25. Riveros-McKay, F., et al., *Genetic architecture of human thinness compared to severe obesity*. PLoS Genet, 2019. **15**(1): p. e1007603.
26. Grove, J., et al., *Identification of common genetic risk variants for autism spectrum disorder*. Nat Genet, 2019. **51**(3): p. 431-444.
27. Cross-Disorder Group of the Psychiatric Genomics Consortium, *Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis*. Lancet, 2013.
28. Adams, H.H., et al., *Novel genetic loci underlying human intracranial volume identified through genome-wide association*. Nat Neurosci, 2016. **19**(12): p. 1569-1582.
29. Pedregosa, F., et al., *Scikit-learn: Machine Learning in Python*. Journal of Machine Learning Research, 2011. **12**: p. 2825–2830.
30. Wolpert, D.H. and W.G. Macready, *No Free Lunch Theorems for Optimization*. IEEE Transactions on Evolutionary Computation 1997. **1**(1): p. 1-32.
31. Wray, N.R., et al., *The genetic interpretation of area under the ROC curve in genomic profiling*. PLoS Genet, 2010. **6**(2): p. e1000864.

32. Faraone, S.V., *The pharmacology of amphetamine and methylphenidate: Relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities*. *Neurosci Biobehav Rev*, 2018. **87**: p. 255-270.
33. Faraone, S.V. and J. Biederman, *Neurobiology of attention-deficit hyperactivity disorder*. *Biological Psychiatry*, 1998. **44**(10): p. 951-958.
34. Hoogman, M., et al., *Subcortical brain volume differences in participants with attention deficit hyperactivity disorder in children and adults: a cross-sectional mega-analysis*. *Lancet Psychiatry*, 2017. **4**(4): p. 310-319.
35. Perlich, C., *Learning Curves in Machine Learning*, in *Encyclopedia of Machine Learning*, C. Sammut and G.I. Webb, Editors. 2010, Springer US: Boston, MA. p. 577-580.

## Supplementary Material

### Improving Machine Learning Prediction of ADHD Using Gene Set Polygenic Risk Scores and Risk Scores from Genetically Correlated Phenotypes

Eric Barnett<sup>1,2</sup>, Yanli Zhang-James<sup>3</sup>, Stephen V Faraone<sup>1,3\*</sup>

#### Affiliations

<sup>1</sup>Department of Neuroscience and Physiology, SUNY Upstate Medical University, Syracuse, New York, USA

<sup>2</sup>College of Medicine, MD Program, SUNY Upstate Medical University, Syracuse, New York, USA

<sup>3</sup>Department of Psychiatry and Behavioral Sciences, SUNY Upstate Medical University, Syracuse, New York, USA

Gene Set	Mean PEM	Predicted PEM	MAGMA p-value	Average RF Importance	Number of SNPs	Number of Genes
GO_NEURON_PROJECTION	0.155	0.175	8.22E-05	0.021	44788	1177
GO_NEUROGENESIS	0.122	0.162	3.34E-04	0.018	52201	1462
GO_SYNAPSE	0.173	0.162	3.30E-07	0.018	47230	1197
GO_SYNAPTIC_SIGNALLING	0.199	0.160	4.48E-05	0.017	26641	672
GO_NEURON_DIFFERENTIATION	0.128	0.150	1.84E-04	0.015	45854	1225
GO_POSITIVE_REGULATION_OF_NUCLEOBASE_CONTAINING_COMPOUND_METABOLIC_PROCESS	0.048	0.139	1.17E-03	0.013	36750	1668
GO_POSTSYNAPSE	0.196	0.134	2.00E-08	0.012	24875	552
GO_REGULATION_OF_NEURON_DIFFERENTIATION	0.136	0.133	1.81E-03	0.012	23279	589
GO_SOMATODENDRITIC_COMPARTMENT	0.164	0.133	6.08E-05	0.011	26955	742
GO_DENDRITIC_TREE	0.171	0.131	2.43E-04	0.011	20277	537
GO_CENTRAL_NERVOUS_SYSTEM_DEVELOPMENT	0.121	0.130	4.78E-04	0.011	30812	878
GO_TRANSPORTER_COMPLEX	0.189	0.129	1.56E-04	0.010	13731	296
GO_NEURON_DEVELOPMENT	0.131	0.128	8.65E-04	0.010	40088	1006
GO_POSITIVE_REGULATION_OF_RNA_METABOLIC_PROCESS	0.048	0.122	1.33E-03	0.009	33699	1531
GO_RNA_BINDING	0.033	0.122	1.27E-03	0.009	26160	1439
GO_CELLULAR_RESPONSE_TO_ENDOGENOUS_STIMULUS	0.067	0.119	1.19E-03	0.007	33746	1313
GO_NEGATIVE_REGULATION_OF_NUCLEOBASE_CONTAINING_COMPOUND_METABOLIC_PROCESS	0.046	0.118	1.84E-04	0.008	26086	1270
GO_CHROMOSOME	0.046	0.118	4.21E-05	0.008	29296	1518
GO_REGULATION_OF_PROTEIN_MODIFICATION_PROCESS	0.060	0.117	1.27E-02	0.009	40580	1663
GO_AXON	0.173	0.116	2.82E-04	0.007	21993	559
GO_POSITIVE_REGULATION_OF_PROTEIN_METABOLIC_PROCESS	0.053	0.116	1.29E-02	0.006	36597	1538
GO_NEGATIVE_REGULATION_OF_BIOSYNTHETIC_PROCESS	0.047	0.115	4.51E-04	0.007	28004	1373
GO_HEAD_DEVELOPMENT	0.117	0.114	3.91E-04	0.007	23700	687
GO_REGULATION_OF_TRANSFERASE_ACTIVITY	0.061	0.114	1.58E-03	0.049	21424	872
GO_RESPONSE_TO_ENDOGENOUS_STIMULUS	0.066	0.114	3.77E-03	0.052	38639	1555
GO_POSITIVE_REGULATION_OF_TRANSFERASE_ACTIVITY	0.062	0.113	7.18E-04	0.046	15661	595
GO_RESPONSE_TO_HORMONE	0.061	0.113	5.64E-03	0.052	21031	918
GO_CELLULAR_RESPONSE_TO_NITROGEN_COMPOUND	0.076	0.113	4.39E-04	0.046	16495	640
GO_NEURON_TO_NEURON_SYNAPSE	0.212	0.112	2.18E-05	0.006	16050	325
GO_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND	0.063	0.111	1.15E-03	0.045	35199	1539
GO_NUCLEAR_CHROMOSOME	0.052	0.111	1.61E-05	0.006	21387	1111
GO_CELLULAR_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND	0.064	0.110	2.97E-03	0.046	25840	1086
GO_CATION_CHANNEL_COMPLEX	0.215	0.110	5.54E-05	0.006	11063	200
GO_REGULATION_OF_KINASE_ACTIVITY	0.063	0.110	1.43E-03	0.043	19777	779
GO_DOUBLE_STRANDED_DNA_BINDING	0.051	0.109	4.80E-06	0.006	17968	866
GO_CELLULAR_RESPONSE_TO_HORMONE_STIMULUS	0.061	0.109	2.51E-03	0.043	16003	649
GO_PROTEIN_MODIFICATION_BY_SMALL_PROTEIN_CONJUGATION_OR_REMOVAL	0.045	0.109	8.42E-04	0.006	19940	958
GO_REGULATION_OF_MEMBRANE_POTENTIAL	0.172	0.109	8.97E-04	0.006	15905	385
GO_DNA_BINDING_TRANSCRIPTION_FACTOR_ACTIVITY_RNA_POLYMERASE_II_SPECIFIC	0.060	0.108	1.33E-03	0.006	19603	964
GO_POSITIVE_REGULATION_OF_KINASE_ACTIVITY	0.067	0.108	6.42E-04	0.039	14412	525
GO_INTRINSIC_COMPONENT_OF_SYNAPTIC_MEMBRANE	0.263	0.108	8.55E-05	0.006	8077	153
GO_NEGATIVE_REGULATION_OF_RNA_BIOSYNTHETIC_PROCESS	0.048	0.108	2.43E-04	0.006	22829	1106
GO_REGULATION_OF_TRANS_SYNAPTIC_SIGNALLING	0.204	0.106	8.09E-03	0.045	17171	412
GO_CHROMATIN	0.053	0.106	3.02E-05	0.005	20269	1061
GO_GLUTAMATERGIC_SYNAPSE	0.199	0.105	1.35E-03	0.006	15563	315
GO_NEGATIVE_REGULATION_OF_TRANSCRIPTION_BY_RNA_POLYMERASE_II	0.048	0.104	9.41E-04	0.005	15842	763
GO_REGULATORY_REGION_NUCLEIC_ACID_BINDING	0.052	0.102	1.14E-06	0.004	17376	851
GO_SEQUENCE_SPECIFIC_DOUBLE_STRANDED_DNA_BINDING	0.053	0.101	3.99E-06	0.004	15772	784
GO_SYNAPTIC_MEMBRANE	0.226	0.101	1.33E-06	0.004	19756	395
GO_INTRINSIC_COMPONENT_OF_POSTSYNAPTIC_MEMBRANE	0.280	0.101	7.87E-05	0.004	6017	112
GO_CHROMOSOME_ORGANIZATION	0.037	0.100	1.78E-04	0.004	21752	1050
GO_MOLECULAR_FUNCTION_REGULATOR	0.071	0.100	2.82E-02	0.060	40366	1635
GO_POSTSYNAPTIC_MEMBRANE	0.234	0.100	1.16E-06	0.004	15750	297
GO_POSITIVE_REGULATION_OF_MOLECULAR_FUNCTION	0.062	0.100	1.51E-02	0.043	43266	1605
GO_POSTSYNAPTIC_SPECIALIZATION_MEMBRANE	0.286	0.099	4.72E-04	0.004	6604	98
GO_SEQUENCE_SPECIFIC_DNA_BINDING	0.054	0.099	6.03E-06	0.003	20120	1046
GO_CELLULAR_RESPONSE_TO_PEPTIDE	0.056	0.099	2.00E-03	0.026	7744	350
GO_ACTION_POTENTIAL	0.149	0.099	5.01E-04	0.004	5298	116
GO_REGULATION_OF_POSTSYNAPTIC_MEMBRANE_POTENTIAL	0.244	0.099	7.07E-03	0.032	6015	129
GO_PROTEIN_MODIFICATION_BY_SMALL_PROTEIN_CONJUGATION	0.045	0.098	1.08E-03	0.004	16670	802
GO_RESPONSE_TO_PEPTIDE	0.055	0.097	1.27E-03	0.004	9833	474
GO_RESPONSE_TO_ANTIOTIC	0.063	0.097	1.35E-02	0.037	6719	297
GO_REGULATION_OF_CATION_CHANNEL_ACTIVITY	0.183	0.097	1.19E-03	0.003	7412	161
GO_RESPONSE_TO_NITROGEN_COMPOUND	0.073	0.096	2.24E-02	0.047	24761	1032
GO_EXCITATORY_SYNAPSE_ASSEMBLY	0.247	0.096	1.96E-04	0.018	1831	25
GO_POSITIVE_REGULATION_OF_SYNAPTIC_TRANSMISSION	0.212	0.096	3.01E-04	0.018	6142	155
GO_REGULATION_OF_SYNAPTIC_PLASTICITY	0.233	0.096	1.15E-03	0.019	7063	172
GO_CYOKINEMEDIATED_SIGNALLING_PATHWAY	0.030	0.096	9.06E-03	0.029	12554	704
GO_CIS_REGULATORY_REGION_BINDING	0.048	0.095	5.95E-04	0.003	10191	542
GO_RESPONSE_TO_OXIDATIVE_STRESS	0.048	0.095	1.56E-02	0.037	8910	405
GO_SECRETION	0.070	0.095	2.02E-02	0.041	35079	1516
GO_POSTSYNAPTIC_SPECIALIZATION_ASSEMBLY	0.285	0.094	1.82E-03	0.017	1795	21
GO_GABAERGIC_SYNAPSE	0.274	0.094	1.12E-03	0.016	4259	63
GO_CHROMATIN_ORGANIZATION	0.041	0.094	1.16E-04	0.002	13964	666
GO_CELL_SURFACE_RECEPTOR_SIGNALLING_PATHWAY_INVOLVED_IN_CELL_CELL_SIGNALLING	0.082	0.093	1.32E-02	0.031	16639	566
GO_RESPONSE_TO_REACTIVE_OXYGEN_SPECIES	0.048	0.093	9.11E-03	0.025	4290	203
GO_TUBULE	0.138	0.093	2.36E-04	0.002	2190	50
GO_ANTEROGRADE_AXONAL_TRANSPORT	0.172	0.093	2.26E-04	0.002	1406	45
GO_REGULATION_OF_POSTSYNAPTIC_SPECIALIZATION_ASSEMBLY	0.300	0.092	1.31E-03	0.014	1421	13
GO_CELLULAR_RESPONSE_TO_REACTIVE_OXYGEN_SPECIES	0.048	0.092	3.22E-03	0.016	2838	143
GO_INTRINSIC_COMPONENT_OF_POSTSYNAPTIC_SPECIALIZATION_MEMBRANE	0.291	0.092	5.56E-04	0.002	4410	72
GO_CELLULAR_RESPONSE_TO_PEPTIDE_HORMONE_STIMULUS	0.056	0.092	9.62E-03	0.024	6544	291
GO_TRANSMEMBRANE_RECEPTOR_PROTEIN_TYROSINE_KINASE_SIGNALLING_PATHWAY	0.064	0.092	1.92E-02	0.036	19320	651
GO_POSITIVE_REGULATION_OF_CATALYTIC_ACTIVITY	0.060	0.092	2.73E-02	0.046	34892	1289
GO_NEURON_SPINE	0.192	0.092	2.49E-04	0.002	6656	134
GO_NEURON_TO_NEURON_SYNAPSE	0.212	0.092	1.84E-02	0.035	16050	350
GO_POSTSYNAPSE_ASSEMBLY	0.265	0.092	2.55E-03	0.015	2480	28
GO_AXON_CYTOSOLASM	0.149	0.092	6.45E-05	0.002	1705	52
GO_NEURON_PROJECTION_CYTOSOLASM	0.143	0.092	1.42E-04	0.002	2480	76
GO_DENDRITIC_SPINE_MORPHOGENESIS	0.185	0.091	1.52E-03	0.012	2708	51
GO_REGULATION_OF_EXCITATORY_SYNAPSE_ASSEMBLY	0.279	0.091	3.98E-04	0.010	1432	15
GO_POSITIVE_REGULATION_OF_ENDOTHELIAL_CELL_MIGRATION	0.032	0.091	6.05E-03	0.017	2750	92
GO_CALCIIUM_CHANNEL_COMPLEX	0.156	0.091	6.48E-05	0.001	3335	60
GO_NEGATIVE_REGULATION_OF_CATABOLIC_PROCESS	0.050	0.090	1.15E-02	0.023	7134	276
GO_RESPONSE_TO_PEPTIDE_HORMONE	0.055	0.090	1.41E-02	0.026	8333	395
GO_REGULATION_OF_DENDRITE_DEVELOPMENT	0.154	0.090	7.69E-03	0.018	7153	136
GO_REGULATION_OF_DENDRITIC_SPINE_MORPHOGENESIS	0.169	0.090	1.71E-03	0.010	1881	40
GO_POSITIVE_REGULATION_OF_EXCITATORY_POSTSYNAPTIC_POTENTIAL	0.273	0.090	6.99E-04	0.009	1561	25
GO_REGULATION_OF_SYNAPTIC_PLASTICITY	0.233	0.090	1.57E-03	0.002	7063	168
GO_LONG_TERM_SYNAPTIC_POTENTIATION	0.227	0.090	1.75E-03	0.010	3139	82

## Summary Statistics with Source Links

ID	Accessibility	Trait.x	rg	abs(rg)	se	z	P	P.bon	PMID	Year	uniqTrait	Population	Case	Control	N	SNP.h2	File
3304	Free download	Age first had sexual intercourse	-0.584	0.584	0.031	-18.938	0	0	31427789	2019	Age first had sexual intercourse	UKB2 (EUR)	NA	NA	339614	0.1132	<a href="https://atlas.ctglab.nl/ukb2_sumstats/f.2139.0.0_res.EUR.sumstats.MACfilt.txt.gz">https://atlas.ctglab.nl/ukb2_sumstats/f.2139.0.0_res.EUR.sumstats.MACfilt.txt.gz</a>
4230	Free download	Opioids	0.565	0.565	0.045	12.55	4.09E-36	5.05E-33	31015401	2019	Opioids	UKB2 (EUR)	22982	55826	78808	0.146	<a href="http://cnsgenomics.com/data/wu_et_al_2019_nc/23_medication-taking_GWAS_summary_statistics.tar.gz">http://cnsgenomics.com/data/wu_et_al_2019_nc/23_medication-taking_GWAS_summary_statistics.tar.gz</a>
58	Free download	College completion	-0.524	0.524	0.052	-10.104	5.30E-24	6.54E-21	23722424	2013	College completion	EUR	NA	NA	95427	0.105	<a href="http://ssgac.org/documents/SSGAC_Rietveld2013.zip">http://ssgac.org/documents/SSGAC_Rietveld2013.zip</a>
59	Free download	Childhood IQ	-0.461	0.461	0.089	-5.163	2.42E-07	0.000299	23358156	2014	Childhood IQ	EUR	NA	NA	12441	0.2744	<a href="http://ssgac.org/documents/CHIC_Summary_Benjamin2014.txt.gz">http://ssgac.org/documents/CHIC_Summary_Benjamin2014.txt.gz</a>
4297	Free download	Extreme obesity (childhood)	0.436	0.436	0.071	6.136	8.45E-10	1.04E-06	30677029	2019	Extreme obesity	EUR	1456	6460	7916	0.5078	<a href="ftp://ftp.ebi.ac.uk/pub/databases/gwas/summary_statistics/Riveros-McKayF_30677029_GCST007241/SCOOP_UKHLS_ldcorrected.gz">ftp://ftp.ebi.ac.uk/pub/databases/gwas/summary_statistics/Riveros-McKayF_30677029_GCST007241/SCOOP_UKHLS_ldcorrected.gz</a>
4037	Free download	Autism spectrum disorder	0.384	0.384	0.053	7.193	6.35E-13	7.84E-10	30804558	2019	Autism spectrum disorder	EUR	18381	27969	46350	0.1944	<a href="https://www.med.unc.edu/pgc/results-and-downloads/downloads">https://www.med.unc.edu/pgc/results-and-downloads/downloads</a>
3219	Free download	Time spent watching television (TV)	0.372	0.372	0.032	11.766	5.86E-32	7.24E-29	31427789	2019	Time spent watching television	UKB2 (EUR)	NA	NA	365236	0.1023	<a href="https://atlas.ctglab.nl/ukb2_sumstats/f.1070.0.0_res.EUR.sumstats.MACfilt.txt.gz">https://atlas.ctglab.nl/ukb2_sumstats/f.1070.0.0_res.EUR.sumstats.MACfilt.txt.gz</a>
1191	Free download	PGC cross disorder	0.262	0.262	0.053	4.954	7.28E-07	0.000898	23453885	2013	PGC cross disorder	EUR	33332	27888	61220	0.1715	<a href="https://www.med.unc.edu/pgc/results-and-downloads">https://www.med.unc.edu/pgc/results-and-downloads</a>
1226	Free download	Intracranial Volume	-0.248	0.248	0.058	-4.314	1.60E-05	0.0198	27694991	2016	Intracranial Volume	EUR	NA	NA	26577	0.2467	<a href="http://enigma.ini.usc.edu/research/download-enigma-gwas-results/">http://enigma.ini.usc.edu/research/download-enigma-gwas-results/</a>
3366	Free download	Age at menopause (last menstrual period) (female)	-0.226	0.226	0.039	-5.844	5.08E-09	6.27E-06	31427789	2019	Age at menopause	UKB2 (EUR)	NA	NA	119160	0.118	<a href="https://atlas.ctglab.nl/ukb2_sumstats/f.3581.0.0_res.EUR.sumstats.MACfilt.txt.gz">https://atlas.ctglab.nl/ukb2_sumstats/f.3581.0.0_res.EUR.sumstats.MACfilt.txt.gz</a>
3539	Free download	Reason for glasses/contact lenses: For short-sightedness, i.e. only or mainly for distance viewing such as driving, cinema etc (called 'myopia')	-0.217	0.217	0.048	-4.523	6.08E-06	0.0075	31427789	2019	Reason for glasses/contact lenses: For short-sightedness	UKB2 (EUR)	32082	46565	78647	0.1532	<a href="https://atlas.ctglab.nl/ukb2_sumstats/6147_1_logistic.EUR.sumstats.MACfilt.txt.gz">https://atlas.ctglab.nl/ukb2_sumstats/6147_1_logistic.EUR.sumstats.MACfilt.txt.gz</a>